文献速递慢性静脉疾病

开放浅静脉手术后静脉曲张复发评分(VVR)的建立与内部验证

Development and internal validation of a new Varicose Vein Recurrence Score for open superficial venous surgery.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-07-24

本研究基于单中心12480条肢体回顾性队列,建立并内部验证了预测开放浅静脉手术后5年复发的VVR评分。六个术前预测因子被保留,乐观校正C统计量为0.744,评分将患者分为低、中、高、极高四个5年复发风险类别。

要点

  • VVR评分包含六个术前临床及双功超声参数,总分0-13分。
  • 5年复发率25.1%,复发肢体中74.1%接受了再干预。
  • 评分将患者分为低(12.8%)、中(25.2%)、高(41.7%)、极高(66.8%)四个5年复发风险类别。

核心结论

  • VVR评分是内部验证的工具,用于估计开放浅静脉手术后5年复发风险。

研究设计与样本

  • 回顾性单中心队列研究,纳入2006年1月至2025年12月间接受大隐静脉-股静脉或小隐静脉-腘静脉交界结扎伴或不伴主干剥脱及同期静脉切除术的连续患者。
  • 主要分析基于5年结局完整确定的肢体,共10142条(占符合条件12480条肢体的81.3%),来自9210例患者。

主要发现

  • 5年复发率为25.1%(2546/10142),复发肢体中74.1%接受了再干预,5年再干预率为18.6%。
  • 保留的六个术前预测因子及OR(95%CI)为:前隐静脉反流2.33(2.03-2.67)、功能不全穿通静脉2.04(1.77-2.35)、BMI≥30 kg/m2 1.82(1.60-2.07)、深静脉反流或梗阻1.72(1.44-2.06)、CEAP C4-C6 1.62(1.42-1.86)、大隐静脉直径≥7 mm 1.41(1.23-1.62)。
  • 乐观校正C统计量为0.744(95%CI 0.726-0.762),校准斜率0.97(0.924-1.016),截距-0.02(-0.06至0.02);再干预终点的C统计量为0.73。

关键数值与推荐

  • VVR评分总分0-13分,将患者分为低(12.8%)、中(25.2%)、高(41.7%)、极高(66.8%)四个5年复发风险类别。

临床怎么用

  • VVR评分可用于开放浅静脉手术术前风险评估,帮助识别高复发风险患者并指导个体化决策。
  • 在更广泛临床采用前,需在地理多样的开放手术队列中进行外部验证,并在内热、非热或泡沫硬化治疗人群中重新推导或校准。

局限性

  • 回顾性单中心设计,仅进行内部验证,需外部验证。
  • 评分在开放手术人群中推导,不能直接用于内热、非热或泡沫硬化治疗人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence after open superficial venous surgery occurs in 20% to 60% of patients at 5 years, yet no validated composite preoperative scoring system exists to quantify individual risk. We aimed to develop and internally validate a predictive model and a derived clinical risk score-the Varicose Vein Recurrence (VVR) Score-for 5-year recurrence after open surgery of the superficial venous system. METHODS: This retrospective single-center cohort study included consecutive patients undergoing saphenofemoral or saphenopopliteal junction ligation with or without trunk stripping and concomitant phlebectomies between January 2006 and December 2025. The primary outcome was duplex-confirmed recurrent reflux with clinically visible recurrent varices at 5 years; reintervention (open, endovenous, or foam) within 5 years served as a prespecified harder secondary end point. The primary analysis was conducted on extremities with complete 5-year outcome ascertainment. We used multivariable logistic regression with cluster-robust standard errors (patient-level clustering) for model development and cluster bootstrap resampling (500 replications) for internal validation. A simplified integer-based score was derived from shrinkage-adjusted coefficients. Prespecified sensitivity analyses included procedure-stratified subgroup models (three mutually exclusive primary subgroups-high ligation + stripping, high ligation alone, and phlebectomy alone-plus an overlapping saphenopopliteal junction-procedure subgroup), continuous calendar-year analyses with time × predictor interactions, treatment choice as a model covariate, inverse probability of censoring weighting, and Cox regression. Reporting followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis guidelines (type 1b). RESULTS: Among 12,480 eligible extremities (9210 patients), 10,142 (81.3%) had complete 5-year ascertainment and constituted the primary cohort. The 5-year recurrence rate was 25.1% (2546/10,142); 74.1% of recurrent extremities underwent reintervention (5-year reintervention rate, 18.6%). Six preoperative predictors were retained: anterior saphenous vein (formerly anterior accessory saphenous vein) reflux (odds ratio [OR], 2.33; 95% confidence interval [CI], 2.03-2.67), incompetent perforators (OR, 2.04; 95% CI, 1.77-2.35), body mass index of ≥30 kg/m2 (OR, 1.82; 95% CI, 1.60-2.07), deep venous reflux or obstruction (OR, 1.72; 95% CI, 1.44-2.06), Clinical, Etiologic, Anatomic, and Pathophysiologic classification C4-C6 (OR, 1.62; 95% CI, 1.42-1.86), and great saphenous vein diameter ≥7 mm (OR, 1.41; 95% CI, 1.23-1.62). The optimism-corrected C-statistic was 0.744 (95% CI, 0.726-0.762), with a calibration slope of 0.97 (0.924-1.016) and an intercept of -0.02 (-0.06 to 0.02). Model performance was preserved for the harder reintervention end point (C-statistic, 0.73) and across operative subgroups (apparent C-statistics, 0.70-0.74). The derived VVR Score (0-13 points) stratified patients into low (12.8%), moderate (25.2%), high (41.7%), and very high (66.8%) 5-year recurrence-risk categories. Continuous calendar-year analysis showed no significant time × predictor interactions (smallest P = .21). Sensitivity analyses including inverse probability of censoring weighting on all 12,480 extremities, Cox regression, generalized estimating equations, and treatment-choice-adjusted models produced consistent results. CONCLUSIONS: The VVR Score provides an internally validated tool for estimating 5-year recurrence risk after open superficial venous surgery using six preoperative clinical and duplex parameters. Performance was preserved across operative subgroups and for the harder reintervention end point. Because the score is derived in an open-surgical population, external validation in geographically diverse open-surgical cohorts and rederivation/recalibration before use in endothermal, nonthermal, or foam-sclerotherapy populations are essential before broader clinical adoption.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Nikolić D, Petrović K, Manojlović V, et al. Development and internal validation of a new Varicose Vein Recurrence Score for open superficial venous surgery. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42497952. doi:10.1016/j.jvsv.2026.102583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。